1Department of Hospital Pathology, College of Medicine, The Catholic University of Korea, Seoul, Korea
2Department of Pathology, Seoul National University Hospital, Seoul National University College of Medicine, Seoul, Korea
3Department of Pathology, Chungnam National University School of Medicine, Daejeon, Korea
4Department of Pathology, CHA Bundang Medical Center, CHA University, Seongnam, Korea
5Department of Pathology, Konkuk University School of Medicine, Seoul, Korea
© 2022 The Korean Society of Pathologists/The Korean Society for Cytopathology
This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
Ethics Statement
All procedures performed in the current study were approved by the Institutional Review Board of the Catholic University of Korea (UC21ZCSI0057) in accordance with the 2018 Helsinki declaration. Formal written informed consent was not required with a waiver by the appropriate the Institutional Review Board of the Catholic University of Korea (UC21ZCSI0057).
Availability of Data and Material
Data sharing not applicable to this article as no datasets were generated or analyzed during the study.
Code Availability
Not applicable.
Author contributions
Conceptualization: YC, DWK. Data curation: YC, JMB, DWK. Formal analysis: YC, JMB, DWK. Funding acquisition: YC, HSH. Investigation: YC, JBM, GK. Methodology: YC, JMB, DWK. Project administration: HSH. Resources: YC, JMB. Software: YC, JMB, GK. Supervision: DWK, HSH. Validation: YC. Visualization: YC. Writing—original draft: YC. Writing—review amp; editing: JMB, DWK, GK, HSH. Approval of final manuscript: all authors.
Conflicts of Interest
YC, a contributing editor of the Journal of Pathology and Translational Medicine, was not involved in the editorial evaluation or decision to publish this article. All remaining authors have declared no conflicts of interest.
Funding Statement
This study was supported by the Korean Society of Pathologists (2020).
Timeline | Checklist preparation process | |
---|---|---|
2020 | May | First draft of DP recommendation consensus paper of KSP DPSG |
June | Initiation of the task force team for developing the DP QAP checklist | |
July | Draft checklist review by DPSG | |
August | Revised checklist review by CQA of KSP | |
September | Peer review of DP recommendation consensus paper by Journal of Pathology and Translational Medicine | |
October | DP recommendation consensus paper published Final review of the DP QAP checklist by CQA of KSP | |
November | Introduction of DP QAP checklist to KSP members during KSP QAP education | |
2021 | June–July | DP QAP trial of 4 hospitals with DP systems |
August–October | Collection of the feedback of DP QAP trial from the technicians, DP users, and managers of 7 hospitals preparing DP systems |
Subjects | Checklist items | Score |
---|---|---|
Quality control of DP systems | 8 | 62 |
Personnel in DP systems | 3 | 16 |
The hardware and software used in DP systems | 9 | 28 |
Operation, management, and validation of DP systems | 15 | 82 |
Personal information protection and information security of DP image data | 4 | 28 |
Total | 39 | 216 |
No. | Checklist item | Score | |
---|---|---|---|
Quality control of DP systems | 62 | ||
01.001 | Do you have laboratory guidelines for DP covering overall DP workflow and is it easily accessible? | 4 | |
01.002 | Does the DP director regularly review and check all guidelines for DP system? | 2 | |
01.003 | If the guidelines are changed, or added, or revised, or partly discarded, does the person in charge of the DP system review and confirm the content? | 2 | |
01.004 | When the DP system director changes, does the new director review and confirm all guidelines? | 4 | |
01.005 | Is there a system to ensure that all employees using the DP system are all aware of the guidelines? | 2 | |
01.006 | Do you have an internal quality control system for the DP system in place and implemented? | 32 | |
01.007 | Do you regularly conduct internal quality control of DP systems? | 8 | |
01.008 | Does the person in charge of the DP systems review and resolve the internal QC results in documentation? | 8 | |
Personnel in DP systems | 16 | ||
02.001 | Are the personnel managing the DP system adequate in numbers? | 4 | |
02.002 | Is the education/training for personnel using/managing DP systems being documented? | 4 | |
02.003 | Are there personnel primarily assigned to whole slide scanning? | 8 | |
The hardware and software used in DP systems | 28 | ||
03.001 | Is the WSS in the DP systems approved by the Ministry of Food and Drug Safety? | 4 | |
03.002 | Is the performance of the WSS regularly checked and maintained by the manufacturer? | 4 | |
03.003 | Is the performance of the WSS and the quality of scanned WSIs regularly evaluated by DP personnel? | 4 | |
03.004 | Does the image database system guarantee that the identification information of the glass slide matches that of the digital image? | 2 | |
03.005 | Even though the version of the image archiving software changes, is it still available to view and use the archived data with a new software without any technical difficulty? | 2 | |
03.006 | Does the image storage method take a form of backup or mirroring? | 4 | |
03.007 | Do the image display devices (e.g., monitor) have the appropriate image quality for primary diagnosis? | 2 | |
03.008 | Does the image viewing software properly implement overview image functions, annotation functions, and image comparison functions to suit the pathological workflow? | 2 | |
03.009 | Are DP systems properly linked to the LIS, EMR, or HIS in an appropriate manner? | 4 | |
Operation, management, and validation of DP systems | 82 | ||
04.001 | Is the laboratory SOP well prepared stating the following? | 10 | |
04.002 | Is an in-house validation on newly introduced devices of DP system being conducted and documented? | 12 | |
04.003 | Is the validation study conducted under conditions that are consistent with the clinical use intended by the DP system manufacturer? | 4 | |
04.004 | Is the validation study designed to be as similar as possible to the actual clinical settings in which the technology will be used? | 4 | |
04.005 | Does the validation study cover the entire DP system? | 4 | |
04.006 | When there are significant changes in the composition of the DP system, is the revalidation on the whole DP system being conducted? Or do you have any guidelines for this? | 8 | |
04.007 | Is the validation intended to be conducted by at least one pathologist who has been acclimated to the DP system? | 4 | |
04.008 | Is the validation carried out using a comparative analysis of concordance between microscopic and WSI-based diagnoses made by a single observer (intra-observer variability assessment)? | 4 | |
04.009 | Did you have a washout period of at least 2 weeks to minimize the influence of recall bias during the validation? | 4 | |
04.010 | During validation, do you assess data integrity of image acquisition by verifying whether all tissues on the glass slide have been properly scanned to form the digital image? | 8 | |
04.011 | Is the additional validation being conducted on the samples for the detection of microorganisms (e.g., Helicobacter pylori), the cytology slides (cell smears, liquid-based cytology, or blood smears), and the cases suspicious for lymphoreticular neoplasms? | 4 | |
04.012 | Are all the errors, its statistics and cause analysis being recorded during the whole slide scanning? | 4 | |
04.013 | Are WSIs being scanned at a minimum magnification of 20x (In case of H&E slides)? | 4 | |
04.014 | Do you manage regular inspection results for the image display device (e.g., monitor)? | 4 | |
04.015 | Is the data being stored according to the data preservation period determined by the individual laboratory? | 4 | |
Personal information protection and information security of DP images | |||
05.001 | Do the guidelines include the instruction and regulation on the collection and management of personal information and information safety? | 16 | |
05.002 | Does the DP guideline specify external personnel or institutions that can access medical information and access data using DP systems? | 4 | |
05.003 | Is there a person in charge of information security for DP system? | 4 | |
05.004 | Is there a suitable system to prevent the loss of personal medical information in case of hardware or software failure in DP system and other emergencies or disasters (e.g., power outages due to natural disasters)? | 4 |
No. | Questionnaire | Answer |
---|---|---|
1 | Please fill in your institute name. | |
2 | What is your current position? | 1) DP director (pathologists) |
2) WSS manager (technician) | ||
3) DP user | ||
3 | In which part DP is being applied? (multiple) | 1) Referred slides |
2) Some H&E slides | ||
3) All H&E slides | ||
4) Special stains | ||
5) IHC stains | ||
6) SISH, IF, FISH | ||
4 | In which part DP will be extended in the future? (multiple) | 1) Referred slides |
2) Some H&E slides | ||
3) All H&E slides | ||
4) Special stains | ||
5) IHC stains | ||
6) SISH, IF, FISH | ||
5 | How many cases are being handled with DP annually? | 1) Less than 5000 cases |
2) 5,000–10,000 cases | ||
3) 10,000–15,000 cases | ||
4) 15,000–25,000 cases | ||
5) 25,000–50,000 cases | ||
6 | How many percentages of cases are being handled with DP annually? | |
7 | Is there any errors or something that needs to be improved in the DP checklist? | |
8 | Is there anything that are unrealistic or | |
9 | Is there anything that needs to be added to the checklist? | |
10 | Do you think the checklist was helpful for preparing in-house QAP or DP guidelines? | 1) Very likely |
2) A little bit | ||
3) I don’t know | ||
4) Not really | ||
5) Not at all | ||
11 | Please share any suggestions to improve DP checklist. |
No. | Checklist items | Score | Lab A | Lab B | Lab C | Lab D | |
---|---|---|---|---|---|---|---|
Quality control of DP systems | 62 | 62 | 62 | 54 | 62 | ||
01.001 | Do you have laboratory guidelines for DP covering overall DP workflow and is it easily accessible? | 4 | 4 | 4 | 4 | 4 | |
01.002 | Does the DP director regularly review and check all guidelines for DP system? | 2 | 2 | 2 | 2 | 2 | |
01.003 | If the guidelines are changed, or added, or revised, or partly discarded, does the person in charge of the DP system review and confirm the content? | 2 | 2 | 2 | 2 | 2 | |
01.004 | When the DP system director changes, does the new director review and confirm all guidelines? | 4 | 4 | 4 | 4 | 4 | |
01.005 | Is there a system to ensure that all employees using the DP system are all aware of the guidelines? | 2 | 2 | 2 | 2 | 2 | |
01.006 | Do you have an internal quality control system for the DP system in place and implemented? | 32 | 32 | 32 | 32 | 32 | |
01.007 | Do you regularly conduct internal quality control of DP systems? | 8 | 8 | 8 | 0 | 8 | |
01.008 | Does the person in charge of the DP systems review and resolve the internal QC results in documentation? | 8 | 8 | 8 | 8 | 8 | |
Personnel in DP systems | 16 | 16 | 8 | 16 | 16 | ||
02.001 | Are the personnel managing the DP system adequate in numbers? | 4 | 4 | 4 | 4 | 4 | |
02.002 | Is the education/training for personnel using/managing DP systems being documented? | 4 | 4 | 4 | 4 | 4 | |
02.003 | Are there personnel primarily assigned to whole slide scanning? | 8 | 8 | 0 | 8 | 8 | |
The hardware and software used in DP systems | 28 | 28 | 28 | 28 | 28 | ||
03.001 | Is the WSS in the DP systems approved by the Ministry of Food and Drug Safety? | 4 | 4 | 4 | 4 | 4 | |
03.002 | Is the performance of the WSS regularly checked and maintained by the manufacturer? | 4 | 4 | 4 | 4 | 4 | |
03.003 | Is the performance of the WSS and the quality of scanned WSIs regularly evaluated by DP personnel? | 4 | 4 | 4 | 4 | 4 | |
03.004 | Does the image database system guarantee that the identification information of the glass slide matches that of the digital image? | 2 | 2 | 2 | 2 | 2 | |
03.005 | Even though the version of the image archiving software changes, is it still available to view and use the archived data with a new software without any technical difficulty? | 2 | 2 | 2 | 2 | 2 | |
03.006 | Does the image storage method take a form of backup or mirroring? | 4 | 4 | 4 | 4 | 4 | |
03.007 | Do the image display devices (e.g., monitor) have the appropriate image quality for primary diagnosis? | 2 | 2 | 2 | 2 | 2 | |
03.008 | Does the image viewing software properly implement overview image functions, annotation functions, and image comparison functions to suit the pathological workflow? | 2 | 2 | 2 | 2 | 2 | |
03.009 | Are DP systems properly linked to the LIS, EMR, or HIS in an appropriate manner? | 4 | 4 | 4 | 4 | 4 | |
Operation, management, and validation of DP systems | 82 | 82 | 78 | 82 | 75 | ||
04.001 | Is the laboratory SOP well prepared stating the following? | 10 | 10 | 10 | 10 | 9 | |
04.002 | Is an in-house validation on newly introduced devices of DP system being conducted and documented? | 12 | 12 | 12 | 12 | 12 | |
04.003 | Is the validation study conducted under conditions that are consistent with the clinical use intended by the DP system manufacturer? | 4 | 4 | 4 | 4 | 4 | |
04.004 | Is the validation study designed to be as similar as possible to the actual clinical settings in which the technology will be used? | 4 | 4 | 4 | 4 | 4 | |
04.005 | Does the validation study cover the entire DP system? | 4 | 4 | 4 | 4 | 4 | |
04.006 | When there are significant changes in the composition of the DP system, is the revalidation on the whole DP system being conducted? Or do you have any guidelines for this? | 8 | 8 | 8 | 8 | 8 | |
04.007 | Is the validation intended to be conducted by at least one pathologist who has been acclimated to the DP system? | 4 | 4 | 4 | 4 | 4 | |
04.008 | Is the validation carried out using a comparative analysis of concordance between microscopic and WSI-based diagnoses made by a single observer (intra-observer variability assessment)? | 4 | 4 | 4 | 4 | 4 | |
04.009 | Did you have a washout period of at least 2 weeks to minimize the influence of recall bias during the validation? | 4 | 4 | 4 | 4 | 4 | |
04.010 | During validation, do you assess data integrity of image acquisition by verifying whether all tissues on the glass slide have been properly scanned to form the digital image? | 8 | 8 | 8 | 8 | 8 | |
04.011 | Is the additional validation being conducted on the samples for the detection of microorganisms (e.g., Helicobacter pylori), the cytology slides (cell smears, liquid-based cytology, or blood smears), and the cases suspicious for lymphoreticular neoplasms? | 4 | 4 | 0 | 4 | 4 | |
04.012 | Are all the errors, its statistics and cause analysis being recorded during the whole slide scanning? | 4 | 4 | 4 | 4 | 4 | |
04.013 | Are WSIs being scanned at a minimum magnification of 20× (In case of H&E slides)? | 4 | 4 | 4 | 4 | 4 | |
04.014 | Do you manage regular inspection results for the image display device (e.g., monitor)? | 4 | 4 | 4 | 4 | 0 | |
04.015 | Is the data being stored according to the data preservation period determined by the individual laboratory? | 4 | 4 | 4 | 4 | 4 | |
Personal information protection and information security of DP images | 28 | 28 | 28 | 28 | 28 | ||
05.001 | Do the guidelines include the instruction and regulation on the collection and management of personal information and information safety? | 16 | 16 | 16 | 16 | 16 | |
05.002 | Does the DP guideline specify external personnel or institutions that can access medical information and access data using DP systems? | 4 | 4 | 4 | 4 | 4 | |
05.003 | Is there a person in charge of information security for DP system? | 4 | 4 | 4 | 4 | 4 | |
05.004 | Is there a suitable system to prevent the loss of personal medical information in case of hardware or software failure in DP system and other emergencies or disasters (e.g., power outages due to natural disasters)? | 4 | 4 | 4 | 4 | 4 | |
Total | 216 | 216 | 204 | 208 | 211 |
DP, digital pathology; QAP, quality assurance program; KSP, Korean Society of Pathologists; DPSG, Digital Pathology Study Group; CQA, Committee of Quality Assurance.
QAP, quality assurance program; DP, digital pathology.
QAP, quality assurance program; DP, digital pathology; QC, quality control; WSS, whole slide scanner; WSI, whole slide imaging; LIS, laboratory information systems; EMR, electronic medical records; HIS, hospital information systems; SOP, Standard Operating Procedures; H&E, hematoxylin and eosin.
DP, digital pathology; QAP, quality assurance program; WSS, whole slide scanner; H&E, hematoxylin and eosin; IHC, immunohistochemistry; SISH, silver in situ hybridization; IF, immunofluorescence; FISH, fluorescence in situ hybridization.
QAP, quality assurance program; DP, digital pathology; QC, quality control; WSS, whole slide scanner; WSI, whole slide imaging; LIS, laboratory information systems; EMR, electronic medical records; HIS, hospital information systems; SOP, Standard Operating Procedures; H&E, hematoxylin and eosin.